+1.84%
Today
Loading 1D prices…
Company profile
RenovoRx, Inc., a clinical-stage biopharmaceutical company, engages in developing targeted combination therapies to improve therapeutic outcomes for cancer patients undergoing treatment. Its lead product candidate is chemotherapy gemcitabine, which is provided through RenovoCath that is in Phase III clinical trials for the treatment of locally advanced pancreatic cancer. The company was founded in 2009 and is headquartered in Mountain View, California.
Sector
Health Care
Industry
Surgical & Medical Instruments & Apparatus
Exchange
Nasdaq
Display currency
USD
Location
MOUNTAIN VIEW, CA, United States
Employees
17
Fiscal year end
1231
CIK
1574094
Session & valuation
Latest annual period
Deterministic peer set
Exact regulatory industry matches, ranked by nearest market capitalization.
| Company | Market cap | Revenue | Net margin | Diluted EPS | Today | Consensus |
|---|---|---|---|---|---|---|
| GUTSFractyl Health Inc. Common Stock | $74.1M | $0.00 | — | -$1.86 | -3.29% | Buy |
| CVRXCVRx Inc. Common Stock | $69.1M | $56.7M | -94.10% | -$2.04 | -6.99% | Hold |
| LUNGPulmonx Corporation Common Stock | $82.4M | $90.5M | -59.67% | -$1.33 | -5.00% | Buy |
| MBOTMicrobot Medical Inc. Common Stock | $85M | $0.00 | — | -$0.29 | 0.00% | Buy |
| DRIODarioHealth Corp. Common Stock | $66.1M | $22.4M | -186.56% | $10.12 | -0.45% | Hold |